- Home
- CLLS vs ADCT Comparison
CLLS vs ADCT Comparison
Compare CLLS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- ADCT
- Stock Information
- Founded
- CLLS 1999
- ADCT 2011
- Country
- CLLS France
- ADCT Switzerland
- Employees
- CLLS N/A
- ADCT N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- ADCT Health Care
- Exchange
- CLLS Nasdaq
- ADCT Nasdaq
- Market Cap
- CLLS 148.1M
- ADCT 131.8M
- IPO Year
- CLLS 2007
- ADCT 2020
- Fundamental
- Price
- CLLS $1.45
- ADCT $1.21
- Analyst Decision
- CLLS Buy
- ADCT Strong Buy
- Analyst Count
- CLLS 3
- ADCT 5
- Target Price
- CLLS $7.00
- ADCT $7.75
- AVG Volume (30 Days)
- CLLS 120.5K
- ADCT 373.9K
- Earning Date
- CLLS 05-27-2025
- ADCT 05-05-2025
- Dividend Yield
- CLLS N/A
- ADCT N/A
- EPS Growth
- CLLS N/A
- ADCT N/A
- EPS
- CLLS N/A
- ADCT N/A
- Revenue
- CLLS $49,217,000.00
- ADCT $70,837,000.00
- Revenue This Year
- CLLS $1.26
- ADCT $6.82
- Revenue Next Year
- CLLS N/A
- ADCT $18.56
- P/E Ratio
- CLLS N/A
- ADCT N/A
- Revenue Growth
- CLLS 435.38
- ADCT 1.84
- 52 Week Low
- CLLS $1.10
- ADCT $1.05
- 52 Week High
- CLLS $3.38
- ADCT $5.17
- Technical
- Relative Strength Index (RSI)
- CLLS 60.38
- ADCT 39.36
- Support Level
- CLLS $1.40
- ADCT $1.13
- Resistance Level
- CLLS $1.56
- ADCT $1.25
- Average True Range (ATR)
- CLLS 0.09
- ADCT 0.11
- MACD
- CLLS 0.03
- ADCT 0.00
- Stochastic Oscillator
- CLLS 76.09
- ADCT 39.51
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.